SCHEMBL308343

SCHEMBL308343

O=c1ccc2cc3ccc(O)cc3oc-2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 1/20 0.67
PTGS1 P23219 2/20 0.60
TYR P14679 1/20 0.60
PTGS2 P35354 1/20 0.60
PDE4B Q07343 1/20 0.60
PDE4D Q08499 1/20 0.60
CALCRL Q16602 2/20 0.57
ESR2 Q92731 1/20 0.55
APP P05067 2/20 0.55
MIF P14174 6/20 0.52
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 3/20 0.51
HPGD P15428 3/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
HSD17B10 Q99714 2/20 0.51
GLA P06280 2/20 0.51
GAA P10253 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
CA12 O43570 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30151888 0.86 SHBG (0.57) SHBGPTGS1TYRPTGS2PDE4B
SCHEMBL9138143 0.80 SHBG (1.00) SHBGPTGS1TYRPTGS2PDE4B
SCHEMBL307532 0.80 EGFR (0.47) SHBGAPPKDM4EALDH1A1HPGD
SCHEMBL223274 0.77 PTPRC (0.59) TYRESR2KDM4EALDH1A1HPGD
SCHEMBL29791652 0.77 PTPRC (0.59) TYRESR2KDM4EALDH1A1HPGD
SCHEMBL5656896 0.77 KDM4E (0.49) SHBGAPPKDM4EALDH1A1HPGD
SCHEMBL28348664 0.76 PTPRC (0.58) TYRESR2KDM4EALDH1A1HPGD
Moracin M SCHEMBL29979946 0.75 PDE4D (1.00) SHBGPTGS1TYRPTGS2PDE4B
Moracin M SCHEMBL1740981 0.75 PDE4D (1.00) SHBGPTGS1TYRPTGS2PDE4B
SCHEMBL733973 0.75 SHBG (0.80) SHBGPTGS1TYRPTGS2PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025264603-A1 THERMAL MANAGEMENT FLUID COMPOSITIONS CONTAINING RECLAIMED MATERIALS THE CHEMOURS COMPANY FC, LLC (US) 2025-12-26 WO claimed
US-20250066653-A1 FLUOROOLEFIN COMPOSITIONS CONTAINING A DYE AND METHODS FOR THEIR PRODUCTION, STORAGE AND USAGE THE CHEMOURS COMPANY FC, LLC (US) 2025-02-27 US claimed
EP-4466323-A1 FLUOROOLEFIN COMPOSITIONS CONTAINING A DYE AND METHODS FOR THEIR PRODUCTION, STORAGE AND USAGE The Chemours Company FC, LLC (US) 2024-11-27 EP claimed
CN-118302501-A Fluoroolefin compositions containing dyes and methods of making, storing and using same 科慕埃弗西有限公司 2024-07-05 CN claimed
WO-2023141098-A1 FLUOROOLEFIN COMPOSITIONS CONTAINING A DYE AND METHODS FOR THEIR PRODUCTION, STORAGE AND USAGE THE CHEMOURS COMPANY FC, LLC (US) 2023-07-27 WO claimed
US-6962992-B2 Crown ether derivatives for use in enhancing transfer of indicators into viabile cells MOLECULLAR PROBES, INC. (US) 2005-11-08 US claimed
US-20020164616-A1 Crown ether derivatives MOLECULAR PROBES, INC. (US) 2002-11-07 US claimed
EP-4684338-A1 SYSTEMS AND METHODS OF RECLAMATION OF THERMAL MANAGEMENT FLUIDS The Chemours Company FC, LLC (US) 2026-01-28 EP disclosed
WO-2025264603-A1 THERMAL MANAGEMENT FLUID COMPOSITIONS CONTAINING RECLAIMED MATERIALS THE CHEMOURS COMPANY FC, LLC (US) 2025-12-26 WO disclosed
US-12487180-B2 Device and methods for quantifying analytes introduction Life Technologies Corporation (US) 2025-12-02 US disclosed
EP-4633458-A1 SYSTEMS AND METHODS FOR ANALYTE DETECTION Adaptyx Biosciences, Inc. (US) 2025-10-22 EP disclosed
EP-4565237-A1 PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF GLIOMA Chimerix, Inc. (US) 2025-06-11 EP disclosed
CN-119997956-A Pharmaceutical composition and use thereof for treating glioma 奇默里克斯公司 2025-05-13 CN disclosed
US-6162931-A Fluorinated xanthene derivatives MOLECULAR PROBES, INC. (US) 2000-12-19 US disclosed
US-6130101-A FLUORESCENT PROBES FOR USE IN BIOLOGICAL SAMPLES MOLECULAR PROBES, INC. (US) 2000-10-10 US disclosed
EP-0853647-A1 FLUORINATED XANTHENE DERIVATIVES Molecular Probes Inc. (US) 1998-07-22 EP disclosed
WO-1997039064-A1 FLUORINATED XANTHENE DERIVATIVES MOLECULAR PROBES, INC. (US) 1997-10-23 WO disclosed
US-4652531-A Fluorescent protein binding assays with unsymmetrical fluorescein derivatives SYNTEX (U.S.A.) INC. (US) 1987-03-24 US disclosed
EP-0141962-A1 Hydrazine derivatives of fluorans and use thereof in electrochromic recording systems THE HILTON - DAVIS CHEMICAL COMPANY (US) 1985-05-22 EP disclosed
US-4439356-A XANTHENES, IMMUNOASSAY SYVA COMPANY (US) 1984-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020164616-A1 Crown ether derivatives CD2, SLC40A1, NCOA1 SHBG 1868/4885PTGS1 1738/4885TYR 2679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.